Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis Antoine Regnault, Maria-Magdalena Balp, Károly.

Slides:

Advertisements

Similar presentations

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Advertisements

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Treatment compliance in children and adults with Cystic Fibrosis

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Towards an individualized protocol for workload increments in cardiopulmonary exercise testing in children and adolescents with cystic fibrosis H.J.

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

Cirrhosis and other liver disease in cystic fibrosis

David N. Sheppard Journal of Cystic Fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Vitamin A and lung function in CF

Prenatal diagnosis for CF using High Resolution Melting Analysis and simultaneous haplotype analysis through QF-PCR Myrto Poulou, Aspasia Destouni, Georgia.

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

A.H. Gifford Journal of Cystic Fibrosis

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure I.J. Clifton, A.M. Morton, N.S. Ambrose,

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis Joseph M. Collaco, Karen S. Raraigh, Lawrence.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis Antoine Regnault, Maria-Magdalena Balp, Károly Kulich, Muriel Viala-Danten Journal of Cystic Fibrosis Volume 11, Issue 6, Pages 494-501 (December 2012) DOI: 10.1016/j.jcf.2012.04.007 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Hypothesized TSQM domain measurement models and impact of the three TSQM treatment-specific aspects (Effectiveness, Side effects, and Convenience) on global satisfaction — results from Structural Equation Modeling (week 5, N=545). This figure summarizes the results of the structural equation model about the link between treatment satisfaction and patient experience with their treatment (Perceived efficacy, side-effects and convenience). This graphical representation combines the specification of how each unobserved variable is measured by the items of the questionnaire and the relationships between the unobserved variables. Ovoids represent unobserved variables; rectangles represent observed variables (items) measuring these unobserved variables; dotted arrows represent the hypothesized links between the variables; parameters relative to each arrow are standardized parameters (that represent the strength of the association between the linked variables). Journal of Cystic Fibrosis 2012 11, 494-501DOI: (10.1016/j.jcf.2012.04.007) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions